
Dr. Lal PathLabs Ltd. has informed the stock exchanges that the boards of its wholly-owned subsidiaries have approved two separate acquisitions. The proposed transactions involve the acquisition of a majority stake in Sunshine Healthcare Limited, Ghana, and a minority stake in Neuome Technologies Private Limited.
The board of Dr. Lal PathLabs FZCO, Dubai, a wholly-owned subsidiary of the company, has approved the acquisition of an 80% equity stake in Sunshine Healthcare Limited (SHL), a diagnostics company based in Ghana.
The acquisition will be carried out for a consideration of up to GHS 45.60 million.
Separately, the board of Dr. Lal Ventures Private Limited, another wholly-owned subsidiary, has approved the acquisition of a 30% equity stake in Neuome Technologies Private Limited.
The proposed investment, valued at up to ₹3.5 crore, will be made through the subscription of equity shares. Neuome develops solutions in sample preservation, pre-analytical technologies and biobanking.
Dr. Lal PathLabs said its Board of Directors took note of the approvals granted by the boards of its two wholly-owned subsidiaries during its meeting held on July 24, 2026. The company disclosed the developments under Regulation 30 of the SEBI Listing Regulations.
Read More: Flipkart to Enter Food Delivery Business, Set to Challenge Zomato and Swiggy!
As of July 24 2026, Dr. Lal PathLabs share price closed at ₹1,759.20 per share, reflecting a surge of 4.27% from the previous trading session.
Dr. Lal PathLabs' wholly-owned subsidiaries have approved the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, and a 30% stake in Neuome Technologies Private Limited. The proposed transactions are subject to the terms disclosed by the company.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 24, 2026, 5:00 PM IST

Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
